DRUG
NASDAQ
US
Bright Minds Biosciences Inc. - common stock
$71.46
▼ $-0.26
(-0.36%)
Vol 188K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$859.9M
ROE
-20.9%
D/E
0.27
Beta
1.62
52W
$33–$132
Wall Street Consensus
7 analysts · Oct 20223
Strong Buy
3
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
CTMX
CytomX Therapeutics Inc
P/E 25.8
$721.8M
CMPX
Compass Therapeutics Inc.
$955.1M
AKTS
Aktis Oncology Inc
CDNA
CareDx Inc
P/E 15.9
$969.0M
INBX
Inhibrx Biosciences Inc
$1.1B
JANX
Janux Therapeutics Inc
$830.0M
MPLT
MapLight Therapeutics Inc
$797.0M
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | $50K | -$3.0M | -$5.2M | -$4.1M | -$7.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -20.9% | -11.0% | -11.0% | -20.9% | -20.9% | -20.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.27 | 0.30 | 0.30 | 0.27 | 0.27 | 0.27 |
| Current Ratio | 86.56 | 88.27 | 88.27 | 86.56 | 86.56 | 86.56 |
Key Ratios
ROA (TTM)
-20.6%
P/B
1.2
EPS (TTM)
$-1.32
CF/Share
$-2.51
52W High
$131.88
52W Low
$33.01
$33.01
52-Week Range
$131.88
Financial Health
Free Cash Flow
-$5.8M
Net Debt
-$88.9M
Cash
$89.0M
Total Debt
$105K
As of Dec 31, 2025
How does DRUG compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DRUG valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.2
▼
52%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DRUG profitability vs Biotechnology peers
ROE
-20.9%
▲
69%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-20.6%
▲
56%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
DRUG financial health vs Biotechnology peers
D/E ratio
0.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
In line
Current ratio
86.6
▲
1850%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.6
▲
67%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
DRUG fundamentals radar
DRUG
Peer median
Industry
DRUG profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DRUG vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
Fryzuk (Jeremy)
Director of Issuer · Feb 24
10000 shs
Fryzuk (Jeremy)
Director of Issuer · Feb 24
7500 shs
Last 90 days
Top Holders
Top 5: 36.6%Janus Henderson Group PLC
11.88%
$81.0M
Cormorant Asset Management,…
10.88%
$74.3M
Vivo Capital, LLC
5.15%
$35.2M
Perceptive Advisors Llc
4.62%
$31.5M
Adage Capital Partners GP L…
4.07%
$27.7M
As of Dec 31, 2025
Latest News
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity …
Nasdaq · Apr 04
Is This Weight Loss Drug Stock a Buy on the Dip?
Nasdaq · Apr 01
Eli Lilly opposes push to pass Trump's drug pricing deals into law, …
CNBC · Apr 01
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico …
Yahoo Finance · Mar 31
O'Reilly Exposes San Francisco As A Violent Third-World Drug Dystopia Infested By …
ZeroHedge · Mar 28